KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Assets (2017 - 2026)

Aquestive Therapeutics has reported Non-Current Assets over the past 9 years, most recently at $11.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 15.51% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $48.1 million, down 14.64%, while the annual FY2025 figure was $11.2 million, 15.51% down from the prior year.
  • Non-Current Assets for Q4 2025 was $11.2 million at Aquestive Therapeutics, down from $11.9 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $17.6 million in Q1 2023 and troughed at $11.2 million in Q4 2025.
  • A 5-year average of $14.7 million and a median of $14.3 million in 2021 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: surged 34.37% in 2023 and later dropped 21.21% in 2024.
  • Year by year, Non-Current Assets stood at $14.7 million in 2021, then rose by 16.61% to $17.2 million in 2022, then decreased by 4.25% to $16.5 million in 2023, then decreased by 19.74% to $13.2 million in 2024, then fell by 15.51% to $11.2 million in 2025.
  • Business Quant data shows Non-Current Assets for AQST at $11.2 million in Q4 2025, $11.9 million in Q3 2025, and $12.0 million in Q2 2025.